Access expanding for experimental weight loss drug
Sentiment Mix
Geography
Expert Signals
CBS News - Top Stories
source • 1 mention
AI-Generated Claims
Generated from linked receipts; click sources for full context.
Drugmaker Eli Lilly says it is expanding access to its experimental weight loss drug, retatrutide, which has not been approved yet by the FDA.
Supported by 1 story
The company says obese patients taking the drug in clinical trials lost between 73 and 85 pounds over two years.
Supported by 1 story
Rachel Pessah Pollack discusses what we know about its safety, who is eligible for the medication and more.
Supported by 1 story
Related Events
CTV Consults Human Health Prof on Kids’ Genetics and Obesity Risk - U of G News
Uncategorized • 8/4/2026
Pixel Watch 5 specs leak reveals what’s new: ‘Accelerated’ chip, 2nd-gen Active Band, more - 9to5Google
Hardware • 8/4/2026
Samsung confirms Galaxy S26 Ultra's red screen issue isn't hardware-related - SamMobile
Uncategorized • 8/4/2026
Mission Artemis II | À quelques heures du retour sur Terre
Product Launch • 8/4/2026
Todd Blanche clears Judiciary Committee hurdle on party lines - Politico
Policy & Regulation • 8/4/2026